Search Results
10
Everything
Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
March 20, 2025 08:30 ET
|
Stemline Therapeutics, Inc.
BPDCN is an aggressive hematologic malignancy with a historically poor prognosisVisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools around...
Tempus and Stemline Therapeutics, Inc., A Subsidiary of the Menarini Group, Announce Collaboration to Implement Tempus Next, an AI-Enabled Care Pathway Intelligence Platform to Support Patients with Metastatic Breast Cancer
February 21, 2025 08:30 ET
|
Stemline Therapeutics, Inc.
Up to 50% of patients with ER+/HER2- mBC could develop ESR1 mutations as a result of prior exposure to endocrine therapy in the metastatic setting. Testing to identify these mutations can help...
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
January 10, 2025 09:00 ET
|
Stemline Therapeutics, Inc.
This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312)...
Aesthetic Threads Market Revenues to Reach USD 204.14 billion by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence
August 01, 2023 09:30 ET
|
Mordor Intelligence
Hyderabad, Aug. 01, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Aesthetic Threads Market Report (2023-2028)," the market is estimated at USD 142.99 billion in 2023. It...
STEMLINE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of STML and Encourages Investors to Contact the Firm
May 19, 2020 12:23 ET
|
Bragar Eagel & Squire
NEW YORK, May 19, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat
December 21, 2018 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat Licensing rights are worldwide excluding US, Canada, Japan and South America Lugano, Switzerland and Florence, Italy,...
Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries
March 02, 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn. and FLORENCE, Italy, March 02, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, and...